172 related articles for article (PubMed ID: 35650630)
21. Parkinson's Disease as a Risk Factor for Prostate Adenocarcinoma: A Molecular Point of View.
Liu T; Yang Z; Liu S; Wei J
Gerontology; 2023; 69(8):986-1001. PubMed ID: 36921580
[TBL] [Abstract][Full Text] [Related]
22. Loss of function of the nuclear envelope protein LEMD2 causes DNA damage-dependent cardiomyopathy.
Caravia XM; Ramirez-Martinez A; Gan P; Wang F; McAnally JR; Xu L; Bassel-Duby R; Liu N; Olson EN
J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36377660
[TBL] [Abstract][Full Text] [Related]
23. Utilizing Ubiquitination Patterns to Predict Prostate Cancer Prognosis and Devise a Therapeutic Response.
Zhang X; Wang Y; Chang Y; Wang J; Yan S; Xiao Y; Guo T; Lou Y; Ma J; Xu W; Ren S
Arch Esp Urol; 2023 May; 76(3):215-231. PubMed ID: 37340527
[TBL] [Abstract][Full Text] [Related]
24. LEM-domain proteins are lost during human spermiogenesis but BAF and BAF-L persist.
Elkhatib RA; Paci M; Boissier R; Longepied G; Auguste Y; Achard V; Bourgeois P; Levy N; Branger N; Mitchell MJ; Metzler-Guillemain C
Reproduction; 2017 Oct; 154(4):387-401. PubMed ID: 28684548
[TBL] [Abstract][Full Text] [Related]
25. The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD).
Xin S; Sun X; Jin L; Li W; Liu X; Zhou L; Ye L
Front Genet; 2022; 13():877278. PubMed ID: 35706452
[TBL] [Abstract][Full Text] [Related]
26. Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer.
Ge H; Yan Y; Yan M; Guo L; Mao K
Med Sci Monit; 2020 Jun; 26():e923208. PubMed ID: 32562536
[TBL] [Abstract][Full Text] [Related]
27. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.
Lee JK; Bangayan NJ; Chai T; Smith BA; Pariva TE; Yun S; Vashisht A; Zhang Q; Park JW; Corey E; Huang J; Graeber TG; Wohlschlegel J; Witte ON
Proc Natl Acad Sci U S A; 2018 May; 115(19):E4473-E4482. PubMed ID: 29686080
[TBL] [Abstract][Full Text] [Related]
28. Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients.
Fei H; Chen X
Am J Cancer Res; 2022; 12(5):2337-2349. PubMed ID: 35693084
[TBL] [Abstract][Full Text] [Related]
29. High expression of KNL1 in prostate adenocarcinoma is associated with poor prognosis and immune infiltration.
Zhang Y; Ji Q; Wang J; Dong Y; Pang M; Fu S; Wei Y; Zhu Q
Front Genet; 2022; 13():1100787. PubMed ID: 36685823
[TBL] [Abstract][Full Text] [Related]
30. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value and potential function of splicing events in prostate adenocarcinoma.
Huang ZG; He RQ; Mo ZN
Int J Oncol; 2018 Dec; 53(6):2473-2487. PubMed ID: 30221674
[TBL] [Abstract][Full Text] [Related]
32. Bioinformatics Analysis of GFAP as a Potential Key Regulator in Different Immune Phenotypes of Prostate Cancer.
Yao W; Li X; Jia Z; Gu C; Jin Z; Wang J; Yuan B; Yang J
Biomed Res Int; 2021; 2021():1466255. PubMed ID: 34222466
[TBL] [Abstract][Full Text] [Related]
33. Comparative Interactome Analysis of Emerin, MAN1 and LEM2 Reveals a Unique Role for LEM2 in Nucleotide Excision Repair.
Moser B; Basílio J; Gotzmann J; Brachner A; Foisner R
Cells; 2020 Feb; 9(2):. PubMed ID: 32085595
[TBL] [Abstract][Full Text] [Related]
34. C10orf116 Gene Copy Number Loss in Prostate Cancer: Clinicopathological Correlations and Prognostic Significance.
Meng J; Wang LH; Zou CL; Dai SM; Zhang J; Lu Y
Med Sci Monit; 2017 Oct; 23():5176-5183. PubMed ID: 29084195
[TBL] [Abstract][Full Text] [Related]
35. Lamina-associated polypeptide (LAP)2α and other LEM proteins in cancer biology.
Brachner A; Foisner R
Adv Exp Med Biol; 2014; 773():143-63. PubMed ID: 24563347
[TBL] [Abstract][Full Text] [Related]
36. Multi-Omics Analysis Reveals Clinical Value and Possible Mechanisms of ATAD1 Down-Regulation in Human Prostate Adenocarcinoma.
Chen CC; Chu PY; Lin HY
Life (Basel); 2022 Oct; 12(11):. PubMed ID: 36362897
[TBL] [Abstract][Full Text] [Related]
37. Identification of FAM107A as a potential biomarker and therapeutic target for prostate carcinoma.
Ma YF; Li GD; Sun X; Li XX; Gao Y; Gao C; Cao KX; Yang GW; Yu MW; Wang XM
Am J Transl Res; 2021; 13(9):10163-10177. PubMed ID: 34650688
[TBL] [Abstract][Full Text] [Related]
38. Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.
Zhao HB; Zeng YR; Han ZD; Zhuo YJ; Liang YK; Hon CT; Wan S; Wu S; Dahl D; Zhong WD; Wu CL
Cancer Sci; 2021 Oct; 112(10):4365-4376. PubMed ID: 34252262
[TBL] [Abstract][Full Text] [Related]
39. Transcriptome Profiles Reveal a 12-Signature Metabolic Prediction Model and a Novel Role of Myo-Inositol Oxygenase in the Progression of Prostate Cancer.
Liu W; Xiang J; Wu X; Wei S; Huang H; Xiao Y; Zhai B; Wang T
Front Oncol; 2022; 12():899861. PubMed ID: 35669435
[TBL] [Abstract][Full Text] [Related]
40. CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer.
Zhou Q; Xiong W; Zhou X; Gao RS; Lin QF; Liu HY; Li JN; Tian XF
Mol Med Rep; 2019 Nov; 20(5):4244-4252. PubMed ID: 31545446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]